CTOR vs TMO · $105.2M cap vs P/E 24, rev $44.56B
Citius Oncology, Inc. (CTOR) versus Thermo Fisher Scientific Inc (TMO) — a side-by-side from cached financials, not a winner call.
Citius Oncology, Inc. (CTOR) is a drug manufacturers - specialty & generic company listed on US.
Thermo Fisher Scientific Inc (TMO) is a diagnostics & research company listed on US.
CTOR does not have a complete income-statement cache yet.
Latest reported TMO revenue for 2025-12-31 was $44.56B. Net income was $6.70B. Revenue was up 3.9% from 2024-12-31 to 2025-12-31. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
CTOR currently screens at market cap $105.2M. TMO currently screens at market cap $153.06B and trailing P/E 23.8.
Not investment advice. Open the CTOR and TMO stock pages for the full models.
Not investment advice.